This is thanks to Lilly's dominance in the billion-dollar weight loss drug market. Lilly's Mounjaro and Zepbound have helped ...

Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 584.52% and ...

Novartis says it's not interested in joining weight-loss drugs frenzy. CEO Vas Narasimhan explained why today on CNBC's "Squawk Box Europe".

With a new investment in its two manufacturing sites in Ireland, Eli Lilly continues implementing the largest expansion ...

AMERICAN pharmaceutical company Eli Lilly has invested US$1bn into the expansion of its manufacturing site in Limerick, ...

Groundbreaking for the Limerick site took place in March 2023, with production expected to commence in 2026. The September 13, 2024 announcement of the additional investment signifies Eli Lilly's ...

Shares of Eli Lilly & Co. LLY shed 1.21% to $923.71 Friday, on what proved to be an all-around positive trading session for ...

While Cork is already successful in the production of industry winners, Eli Lilly's obesity and weight loss drugs are ...

Sold under the brand names Mounjaro and Zepbound, tirzepatide has been an incredible growth driver for Eli Lilly. In 2022 -- the year it was first approved in the U.S. -- some analysts predicted that ...

This additional investment is part of the most ambitious manufacturing expansion agenda in the company's history. Since 2020, ...

Discover Citi's bullish outlook on Eli Lilly with a $1,060 target. Is now the time to invest? Find key insights and price ...